WHO names SynAct Pharma oral resomelagon among six dengue candidates
WHO listed SynAct’s oral therapy resomelagon as one of six dengue drug candidates with supporting efficacy data for further clinical development, per a Lancet Microbe review. SynAct expects Phase 2 RESOVIR-2 results from Part 1 in 2026, pending regulatory feedback.